Summary :- Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option New Drug Application Approval Based on High Rates…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Category:
Regulatory
-
-
Mirati TherapeuticsRegulatoryU.S FDA
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
by adminby adminSummary :-Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted…
-
IndiaLaunch
Indian Farmers Fertiliser Cooperative Limited and Mitsubishi Corporation Launches Takibi (Flubendiamide 20% WG) Insecticide
by adminby adminHighlights : IFFCO and Mitsubishi Corporation formed a joint venture to produce Tabiki (Flubendiamide 20% WG). The major causes of biotic stress…
-
442 RC meetingCIBRC - Indian Pesticide ApprovalsIndiaRC Meeting updates
INDIAN PESTICIDE APPROVALS – 442ND RC MEETING – CHLORANTRANILIPROLE – FMC MOLECULE – MAJOR HIGHLIGHT
by adminby adminINDIAN PESTICIDE APPROVALS UPDATES – MINUTES OF THE 442ND REGISTRATION COMMITTEE (RC) MEETING HELD ON 18.11.2022 The 442nd meeting of the Registration…
-
RegulatoryU.S FDA
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
by adminby adminSummary- The FDA has approved fecal microbiota, live-jslm (Rebyota; Ferring Pharmaceuticals) for the prevention of recurring Clostridioides difficile infection (CDI) among patients 18…
-
RegulatoryU.S FDA
The FDA has Approved TZIELDTM (Teplizumab-mzwv) as the First and Only Medication Intended to Postpone the onset of Stage 3 Type 1 Diabetes (T1D) in Adult and Paediatric Patients with Stage 2 T1D Who are 8 Years of Age and Older.
by adminby adminSummary:- TZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune disease In a clinical trial, in Stage 2 T1D patients,…
-
RegulatoryU.S FDA
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
by adminby adminSummary: Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide…
-
CompaniesPfizerRegulatoryU.S FDA
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for relapsed or Refractory Multiple Myeloma
by adminby adminPfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for…
-
RegulatoryU.S FDA
U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
by adminby adminSummary-The Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3…
-
RegulatoryU.S FDA
Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain
by adminby adminNext Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief…